Professional Memberships:

• PK/PD of Novel Biological Construct; Advisory board member (2013–present)
• Bioanalytical Method & Modeling Integration Summit; Advisory board member (2013–present)
• The 3rd Pharmacokinetics & Pharmacodynamics; Advisory board member (2012–present)
• Global PK/PD Network at Pfizer Inc; • Chair (2011–present)
• The Dean’s Student Ambassador (2008–2010)
• UB-Pharmaceutics Graduate Student Association; President & Vice President (2007–2008)
• American Association of Pharmaceutical Scientists; Member (2004–present)

Presentations:

• "Development of Translational PK Model for Characterizing and Predicting Protein Therapeutics Disposition in Brain" The National Academies of Sciences, Engineering, and Medicine’s Forum on Neuroscience and Nervous System Disorders. (2017)
• "Quantitative Characterization of the Bystander Effect of ADCs." 7th World ADC Summit (2017)
• "Bench-to-bedside translation of ADCs using PKPD M&S" World Conference on Pharmacometrics (WCOP) (2016)
• "Model-based Drug Development of Protein Therapeutics" 11th International International Society for the Study of Xenobiotics (ISSX) Meeting (2016)
• "Platform PBPK Model for Biologics and Its Evolution Towards Pediatric Population" Gordon Research Conference on Drug Metabolism (2015)
• "Model Based Development of Antibody Drug Conjugates" Clinical & Pharmaceutical Solutions through Analysis Conference 2014 (2014)
• "Quantitative PKPD Approaches to Guide the Discovery and Development of ADCs" ; Green Cross Pharmaceuticals (2014)
• "Preclinical to Clinical Translation of Antibody Drug Conjugate (ADC) Efficacy using PK/PD Modeling and Simulation" 2013 AAPS Webinar Series; ; CPTR (2013)
• "Development and Validation of a Mechanism Based PK/PD Model for Preclinical to Clinical Translation of ADC Efficacy" PK/PD of Antibody-Derived Molecules: Improving Pre-Clinical Results for Clinical Success; ; PEGS Inaugural (2013)
• "Development and Validation of the multi-scaled mechanistic PK/PD model for ADCs" PK/PD of Novel Constructs Conference; Cambridge Healthtech Institute (2013)
• "Employing PK/PD modeling and simulation to guide ADC development" 2013 World ADC Summit (2013)
• "Evolving PBPK Modeling to Predict the PK and Appropriate Doses of Biotherapeutics for Pediatric Patients" 2013 AAPS NBC Meeting (2013)
• "Novel Applications of PBPK Models" PK/PD summit (2013)
• "Overcoming PK/PD barriers to link drug levels with the biological effects in a tumor" 2013 Tumor Model Conference (2013)
• "A platform PBPK model to characterize the plasma and tissue disposition of mAbs" The 2012 Rozman Symposium; ; The Delaware Valley DRUG METABOLISM DISCUSSION GROUP (2012)
• "Bench to Bedside Translation of Antibody Drug Conjugates Using a Multiscale Mechanistic PK/PD Model: A Case Study with SGN-35" 2012 World-Wide Webinars: Impact of Modeling and Simulation in Drug Development.; ; ROSA‘s (2012)
• "Preclinical-to-clinical translation of ADC efficacy using the multi-scaled mechanistic PK/PD model" 3rd Pharmacokinetics & Pharmacodynamics Conference; GTC (2012)
• "Using Mechanistic Preclinical PK/PD Studies to Inform Dose, Dose Regimen Selection and Beyond: Can we make Preclinical Models more Predictive?." World ADC Summit (2012)
• "Mechanistic Modeling for Rational Selection of Clinical Doses for Biologics" ; ; AAPS (2011)
• "Treating ovarian cancer using combination of anti-angiogenic therapy and intraperitoneal chemotherapy" ; ; AAPS (2010)
• "Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy" ; University at Buffalo; Pharmaceutical Sciences (2009)
• "A Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy" PGSRM (2009)
• "Application of anti-angiogenic therapy to improve drug penetration in solid tumors, following regional chemotherapy" UB/Pfizer monoclonal antibody videoconference (2007)
• "The role of dehydration and transepidermal water loss in skin barriers function" (2003)